top of page
  • ODI Pharma

Aphria Inc. received its EU-GMP certification

ODI Pharma AB (“ODI Pharma” or “the Company”) hereby announce that Aphria Inc. (“Aphria”), the Company’s supplier of medical cannabis, has received its European Union Good Manufacturing Practices ("EU-GMP") certification as an active substance manufacturer.

The certification will allow Aphria to be a supplier of bulk dried flower for medicinal use worldwide to other EU-GMP certified facilities licensed to further process or package bulk dried flower into finished cannabis product for sale in permitted jurisdictions. For ODI Pharma this certification means that the Company proceeds according to plan to distribute its products in Poland.

CEO Derek Simmross

“We are of course happy that Aphria has now received their EU-GMP certification, which keeps ODI Pharma on track to reach its mid-term targets”.

For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB


ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.

0 Kommentare

Aktuelle Beiträge

Alle ansehen

ODI Pharma AB: Updated market and business overview

ODI Pharma AB (“ODI” or the “Company”) hereby present an updated overview of its market position and the latest trends observed in the cannabis industry, particularly in Europe. Progress in the cooper

ODI Pharma AB: Publication of half-year report 2023/2024

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2023. The report is available as an attached document to this press release and on the Compa


bottom of page